பேயர் ஶரிஂக் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பேயர் ஶரிஂக் மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பேயர் ஶரிஂக் மருந்துகள் Today - Breaking & Trending Today

Versantis AG: Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board

Versantis AG: Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board
Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, today announced the appoint of seasoned pharmaceutical executive Christopher Seaton to its Board of Directors. Mr. Seaton has extensive expertise in business development, with more than 25 years experience in closing transactions of all types, including M&A, licensing, collaborations and partnerships. He also has varied hospital and healthcare board position experience.
Christopher is a very experienced international deal-maker in our industry and comes to Versantis at a pivotal time as we begin to build our clinical experience with VS-01, our lead drug candidate for acute liver and metabolic diseases. He brings a fresh US angle which is well aligned with Versantis goal to grow into an international biopharmaceutical company, said Vincent Forster, Versantis Co-founder and CEO. We welcome Ch ....

United States , Kostenloser Wertpapierhandel , Meriam Kabbaj , Vincent Forster , Mike Sinclair , Christopher Seaton , Bayer Pharmaceuticals , Bayer Ag , Mcmaster University , Bayer Schering Pharmaceuticals , Merck Co , Versanti Co Founder , Senior Vice President , Bayer Healthcare , Bayer Oncology , Rare Pediatric Diseases Designation , ஒன்றுபட்டது மாநிலங்களில் , வின்சென்ட் ஃபார்ஸ்டர் , மைக் சின்க்ளேர் , கிறிஸ்டோபர் சீடன் , பேயர் மருந்துகள் , மக்மாஸ்டர் பல்கலைக்கழகம் , பேயர் ஶரிஂக் மருந்துகள் , மெர்க் இணை , மூத்தவர் துணை ப்ரெஸிடெஂட் , பேயர் சுகாதாரம் ,

Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board

Share:
Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, today announced the appoint of seasoned pharmaceutical executive Christopher Seaton to its Board of Directors. Mr. Seaton has extensive expertise in business development, with more than 25 years experience in closing transactions of all types, including M&A, licensing, collaborations and partnerships. He also has varied hospital and healthcare board position experience.
Christopher is a very experienced international deal-maker in our industry and comes to Versantis at a pivotal time as we begin to build our clinical experience with VS-01, our lead drug candidate for acute liver and metabolic diseases. He brings a fresh US angle which is well aligned with Versantis goal to grow into an international biopharmaceutical company, said Vincent Forster, Versantis Co-founder and CEO. We welcome Christopher to the team and look forward to working with him on building out our pi ....

United States , Meriam Kabbaj , Vincent Forster , Christopher Seaton , Bayer Pharmaceuticals , Bayer Ag , Mcmaster University , Bayer Schering Pharmaceuticals , Merck Co , Versanti Co Founder , Senior Vice President , Bayer Healthcare , Bayer Oncology , Rare Pediatric Diseases Designation , ஒன்றுபட்டது மாநிலங்களில் , வின்சென்ட் ஃபார்ஸ்டர் , கிறிஸ்டோபர் சீடன் , பேயர் மருந்துகள் , மக்மாஸ்டர் பல்கலைக்கழகம் , பேயர் ஶரிஂக் மருந்துகள் , மெர்க் இணை , மூத்தவர் துணை ப்ரெஸிடெஂட் , பேயர் சுகாதாரம் , பேயர் புற்றுநோயியல் , ரேர் குழந்தை நோய்கள் பதவி ,

Autoimmune Treatment Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Press Release

Autoimmune Treatment Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, Dec. 24, 2020 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Autoimmune Treatment Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p05913302/?utm source=GNW
The Global Autoimmune Treatment Market is expected to grow from USD 149,595.74 Million in 2019 to USD 222,840.11 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.86%.
Market Segmentation & Coverage:
This research report categorizes the Autoimmune Treatment to forecast the revenues and analyze the trends in each of the following sub-markets: ....

New York , United States , United Kingdom , South Africa , United Arab Emirates , Saudi Arabia , South Korea , Astellas Pharma , Boehringer Ingelheim Gmbh , Market Development , Biogen Idec Inc , Autoimmune Inc , Astrazeneca Plc , Company Usability Profiles , Angiotech Pharmaceuticals , Autoimmune Treatment Market Research , Biocryst Pharmaceuticals Inc , Bayer Schering Pharmaceuticals , Abbott Laboratories , Product Development Innovation , Bristol Myers Squibb Co , Treatment Market Research Report , Global Autoimmune Treatment Market , Compound Annual Growth Rate , Autoimmune Treatment , Autoimmune Treatment Market ,